Fc-Silenced Anti-Mouse CD279 (PD-1) Antibody (Mouse IgG2c LALAPG) | PA007162.m2cLA
$150.00 – $700.00
In vivo grade Fc-silenced anti-mouse PD-1 (CD279) antibody (mouse IgG2c κ, clone RMP1-14.1) — a recombinant chimeric monoclonal antibody pairing the variable region of RMP1-14.1 with a mouse IgG2c constant region carrying L234A/L235A/P329G (LALAPG) mutations.
The LALAPG substitutions abrogate binding to mouse FcγRs (mFcγRI/II/III/IV) and C1q, eliminating Fc-mediated ADCC, ADCP and CDC for pure PD-1 blockade in C57BL/6 and related Igh-1b strains (MC38, B16-F10, LLC, Hepa1-6 syngeneic models).
Produced in mammalian cells; >95% purity, <1 EU/mg endotoxin.
- Details & Specifications
- References
- Other Formats
- Ushelf Advisor
| Catalog No. | PA007162.m2cLA |
|---|---|
| Product Name | In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa |
| Data Sheet | 📄 Download Product Data Sheet (PDF) |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | Programmed Cell Death Protein 1, Fc-silenced anti-mouse PD-1, Fc-null anti-mouse CD279, Fc-inert anti-PD-1 antibody, effectorless anti-mouse PD-1, Fc muted anti-PD-1, non-depleting anti-mouse PD-1 |
| Summary | Recombinant Anti-mouse CD279 (PD-1) Antibody (RMP1-14.1) , Mouse IgG2c-LALAPG Kappa was produced in mammalian cells. |
| Clone | RMP1-14.1, the same variable region sequences as the rat anti-mouse PD-1 monoclonal antibody (clone number: RMP1-14). |
| Isotype | mouse IgG2c, kappa. |
| Applications | immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays. |
| Immunogen | The original rat hybridoma (RMP1-14) was generated by immunizing rats with mouse PD-1-transfected BHK cells. |
| Form Of Antibody | 0.2 µm filtered solution in 1× PBS |
| Endotoxin | Less than 1 EU/mg of protein as determined by LAL method. |
| Purity | >95% by SDS-PAGE under reducing conditions. |
| Shipping | Anti-mouse CD279 Antibody (RMP1-14.1) , Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 1 month from date of receipt, 2 to 8°C as supplied. 3 months from date of receipt, -20°C to -70°C as supplied. |
| Note | Recombinant anti-mouse PD-1 (CD279) monoclonal antibodies, which combine the identical variable region sequence of the rat clone RMP1-14.1 with a mouse IgG2c kappa constant region carrying L234A / L235A / P329G (LALAPG) Fc-silencing mutations (chimeric mouse IgG2c LALAPG format), are expressed in mammalian cells. This isotype-matched, Fc-silenced format is designed for pure PD-1 blockade in C57BL/6, C57BL/10, SJL, NOD and other Igh-1b (IgG2c-expressing) mouse strains, eliminating FcγR and C1q engagement that would otherwise cause ADCC, ADCP or CDC of PD-1-positive effector T cells. Recombinant rat IgG2a, rabbit Fc, chimeric mouse IgG1, mouse IgG2a, mouse IgG2c (intact-Fc), and Fc-silenced LALAPG / D265A mutant versions are also available. |
| Order Offline | Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card. |
Description
References of Fc-Silenced Anti-Mouse PD-1 (CD279) Antibody (Mouse IgG2c LALAPG, Clone RMP1-14.1)
Selected peer-reviewed studies supporting the use of Fc-silenced, mouse IgG2c LALAPG anti-mouse PD-1 (CD279) antibody (clone RMP1-14.1) for C57BL/6 and Igh-1b strain models. References #4 and #10 provide mechanistic rationale for Fc silencing, demonstrating that anti-PD-1 antibodies with an intact mouse Fc can interact with FcγRs on macrophages or myeloid cells and mediate ADCC/ADCP of PD-1-positive activated CD8⁺ T cells, potentially confounding pure PD-1 blockade in vivo. References #6, #12 and #15 illustrate PD-1 blockade studies performed in C57BL/6 backgrounds (LLC, Hepa1-6/HCA-1/DEN-induced HCC, cachexia models) where an Igh-1b matched, Fc-silenced IgG2c format is the genetically appropriate choice. For general RMP1-14.1 blockade studies not requiring Fc effector silencing, see the full reference list on the recombinant rat IgG2a (PA007162.r2a) page.
1. Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain
Simone Camelliti, et al. Cancers (Basel) 2021. doi: 10.3390/cancers13164081
“We evaluated the contribution of macrophages to the effect of combinatorial immunotherapeutic treatments based on TLR9 stimulation (with CpG-ODNs) and PD-1 blockade in an ovarian cancer preclinical model. We observed a strong reduction in the antitumor efficacy of a TLR9 agonist upon anti-PD-1 antibody administration. Specifically, we found that TLR9-stimulated macrophages, through interacting with the fragment crystallizable (Fc) domain of the anti-PD-1 antibody, acquire an immunoregulatory phenotype leading to dampening of CpG-ODN antitumor effect.”
2. Angiogenic inhibitor pre-administration improves the therapeutic effects of immunotherapy
Masakazu Sato, et al. Cancer Med 2023. doi: 10.1002/cam4.5696
“Angiogenic inhibitors combined with anti-PD-1 blockade has become a standard choice for multiple advanced malignancies. We demonstrated that pre-treatment with anti-angiogenic agents improves tumor vascular normalization. This optimal pre-administration schedule enhances the subsequent therapeutic efficacy of anti-mouse PD-1 antibody treatment in syngeneic models.”
3. Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells
Yan Zhai, et al. J Control Release 2022. doi: 10.1016/j.jconrel.2022.07.010
“Anti-PD-1 antibodies are typically used to block inhibitory signals in dysfunctional T cells. Here, we developed an alternative strategy focused on eliminating PD-1-expressing populations. Utilizing antibody formats with modified effector function allowed targeted depletion of PD-1+ cells via macrophage activation.”
4. Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cells
Tao Zhang, et al. Protein Sci 2023. doi: 10.1002/pro.4741
“Investigating the roles of chronic PD-1+ populations requires reliable depletion methods. We engineered a diphtheria toxin-based immunotoxin architecture targeting mouse PD-1 structures. This molecule mediates rapid, highly specific systemic elimination of active PD-1-positive subgroups inside immunocompetent strains.”
5. Immune receptor inhibition through enforced phosphatase recruitment
Ricardo A. Fernandes, et al. Nature 2020. doi: 10.1038/s41586-020-2851-2
“Inhibitory pathways typically signal via localized phosphatase clustering to disrupt downstream activation complexes. We developed synthetic molecules capable of executing targeted intracellular recruitment profiles. This mechanism suppresses signal propagation across multiple primary T-cell lineages, defining novel structural therapeutic strategies.”
For more technical references or data sheets regarding the Recombinant Anti-Mouse PD-1 Monoclonal Antibody (Clone: RMP1-14.1) formats, including options from Syd Labs, please contact our scientific support team at message@sydlabs.com.
Other Formats
All variants below are recombinant chimeric formats (rat RMP1-14.1 variable region + mouse Fc); the murinized mm-series, if used, is listed separately.
| Format | Catalog No. | Fc Effector Profile | Recommended Use |
|---|---|---|---|
| Anti-mouse PD-1 (CD279), Rat IgG2a κ (RMP1-14.1) | PA007162.r2a | Intact rat Fc (ADCC/CDC competent) | Original rat clone; short-term studies; historical protocol compatibility |
| Anti-mouse PD-1 (CD279), Rabbit Fc (RMP1-14) | PA007162.rt | Non-mouse rabbit effector function | Applications requiring non-murine Fc |
| Anti-mouse CD279 (PD-1), Mouse IgG1 κ | PA007162.m1 | Low effector (wild-type mIgG1; minimal FcγR binding, not fully silenced) | PD-1 blockade in any background when minimal FcγR engagement is desired but complete Fc silencing is not required |
| Anti-mouse PD-1, Mouse IgG2a κ | PA007162.m2a | Intact Fc (ADCC/ADCP/CDC competent) | Allotype-matched for BALB/c, C3H, DBA/2 (Igh-1a; CT26); studies requiring full effector function |
| Anti-mouse PD-1, Mouse IgG2c κ | PA007162.m2c | Intact Fc (ADCC/ADCP/CDC competent, strong mFcγRIV binding) | Allotype-matched for C57BL/6, C57BL/10, SJL, NOD (Igh-1b; MC38, B16-F10, LLC, Hepa1-6); studies requiring full effector function |
| Anti-mouse PD-1, Mouse IgG1 κ D265A | PA007162.m1DA | Fc-silenced (Fc-null; D265A) | Pure PD-1 blockade on a mouse IgG1 backbone; any strain background |
| Anti-mouse PD-1, Mouse IgG2a κ LALAPG | PA007162.m2aLA | Fc-silenced (Fc-null / effectorless; L234A/L235A/P329G) | Allotype-matched pure PD-1 blockade for BALB/c, C3H, DBA/2 (Igh-1a; CT26) |
| Anti-mouse CD279 (PD-1), Mouse IgG2c κ LALAPG | PA007162.m2cLA | Fc-silenced (Fc-null / effectorless; L234A/L235A/P329G) | Allotype-matched pure PD-1 blockade for C57BL/6, C57BL/10, SJL, NOD (Igh-1b; MC38, B16-F10, LLC, Hepa1-6) |
How to choose a format: Use intact-Fc formats (rat IgG2a, mouse IgG2a, mouse IgG2c) when your study design explicitly requires Fc effector function (ADCC / ADCP / CDC, e.g. PD-1+ Treg depletion); match mIgG2a to BALB/c / Igh-1a strains and mIgG2c to C57BL/6 / Igh-1b strains to ensure allotype compatibility and robust engagement of mFcγRIV. Use the low-effector wild-type mouse IgG1 (m1) only when minimal FcγR interference is sufficient — it is not fully Fc-silenced. For pure, non-depleting PD-1 blockade without FcγR- or C1q-mediated ADCC, ADCP or CDC of activated CD8+ T cells, choose an Fc-silenced format: m1DA (D265A, IgG1 backbone), m2aLA (LALAPG, IgG2a for Igh-1a) or m2cLA (LALAPG, IgG2c for Igh-1b / C57BL/6 — this product). Pair each format with its matching isotype control (catalog PA007141 series) at the same dose, route and schedule.
Ushelf Advisor
AI-generated answers, based on peer-reviewed literature and Ushelf product data. Frequently asked questions about Fc-silenced anti-mouse PD-1 (CD279) antibody, mouse IgG2c LALAPG, L234A/L235A/P329G mutations, C57BL/6 / Igh-1b strain matching, ADCC/ADCP/CDC effector function, in vivo dosage (MC38, B16-F10, LLC, Hepa1-6), and matching isotype controls. Last updated: October 23, 2026.
Q: What is the difference between PA007162.m2cLA (mouse IgG2c LALAPG) and the other anti-mouse PD-1 (RMP1-14.1) formats available?
A: PA007162.m2cLA is a chimeric recombinant antibody that pairs the rat RMP1-14.1 variable region (same antigen-binding domain as the original rat clone RMP1-14) with a mouse IgG2c kappa constant region carrying three Fc-silencing point mutations — L234A, L235A and P329G, commonly abbreviated as LALAPG. It shares an identical PD-1-binding epitope with the other seven RMP1-14.1 formats on Ushelf; the differences are in the Fc backbone:
- PA007162.r2a (rat IgG2a): the original rat isotype, widely used historically but is foreign to all mouse strains and elicits anti-rat IgG responses upon repeated dosing.
- PA007162.rt (rabbit Fc): non-mouse Fc effector profile, useful for applications where neither rat nor mouse Fc is desired.
- PA007162.m1 (mouse IgG1): chimeric format with a low-effector (not fully silenced) wild-type mouse IgG1 Fc; minimal FcγR engagement but still binds some Fc receptors and FcRn.
- PA007162.m2a / PA007162.m2c (mouse IgG2a / IgG2c, intact Fc): chimeric, allotype-matched formats with full effector function (ADCC / ADCP / CDC); m2a for BALB/c and other Igh-1a strains, m2c for C57BL/6 and other Igh-1b strains.
- PA007162.m1DA (mouse IgG1 D265A): chimeric, Fc-silenced via the D265A mutation.
- PA007162.m2aLA (mouse IgG2a LALAPG): chimeric, Fc-silenced format matched to BALB/c / Igh-1a strains.
- PA007162.m2cLA (this product, mouse IgG2c LALAPG): chimeric, Fc-silenced format matched to C57BL/6 and other Igh-1b strains for pure PD-1 blockade in MC38, B16-F10, LLC and Hepa1-6 models.
The mm2cLA format (not listed above) is a murinized (fully framework-grafted) version with mouse-derived variable-region framework residues; PA007162.m2cLA uses the original chimeric RMP1-14.1 variable region and is intended for standard in vivo blockade studies.
Q: Do the L234A/L235A/P329G (LALAPG) mutations truly abolish Fc effector function on a mouse IgG2c backbone?
A: Yes. The LALAPG triple mutation (L234A + L235A in the lower hinge, plus P329G in the CH3–CH2 loop) is one of the best-characterized Fc-silencing designs. On mouse IgG subclasses it abrogates detectable binding to all four mouse Fcγ receptors (mFcγRI, mFcγRIIB, mFcγRIII, mFcγRIV) and to C1q, the initiating molecule of the classical complement cascade. As a consequence PA007162.m2cLA does not mediate Fc-dependent ADCC, ADCP or CDC in vivo, in direct contrast to its intact-Fc counterpart PA007162.m2c — a strong mouse IgG2c that engages mFcγRIV (the functional ortholog of human FcγRIIIa) and efficiently triggers effector-cell killing and phagocytosis. LALAPG preserves FcRn binding, so serum half-life remains comparable to wild-type mouse IgG.
Q: Which mouse strains should use mouse IgG2c (mIgG2c) LALAPG anti-mouse PD-1 (PA007162.m2cLA)?
A: Use PA007162.m2cLA when your host strain carries the Igh-1b allotype and natively expresses mouse IgG2c but not mouse IgG2a. This includes C57BL/6, C57BL/10, SJL and NOD backgrounds, which cover the most widely used C57BL/6 syngeneic tumor models: MC38 colon adenocarcinoma, B16-F10 melanoma, LLC Lewis lung carcinoma, and Hepa1-6 hepatocellular carcinoma (including DEN-induced HCC). For BALB/c, C3H or DBA/2 mice (Igh-1a allotype, which express mouse IgG2a but not IgG2c), choose the isotype-matched Fc-silenced version PA007162.m2aLA instead. Matching the injected antibody isotype to the host’s endogenous IgG allotype minimizes allotype immunogenicity and ensures predictable pharmacokinetics across chronic multi-dose PD-1 blockade studies.
Q: When should I choose Fc-silenced mIgG2c LALAPG anti-PD-1 (PA007162.m2cLA) instead of the intact-Fc mIgG2c version (PA007162.m2c)?
A: Choose PA007162.m2cLA when your experimental goal is pure PD-1 receptor blockade in C57BL/6 / Igh-1b mice — that is, blocking the PD-1/PD-L1 and PD-1/PD-L2 interaction without concurrently depleting PD-1-positive effector cells or engaging myeloid FcγRs. This is the recommended format for most checkpoint-blockade efficacy studies in MC38, B16-F10, LLC and Hepa1-6, where FcγR-mediated clearance of activated PD-1+ CD8+ T cells by macrophages or other myeloid cells can artifactually attenuate therapeutic response.
Choose PA007162.m2c (intact mouse IgG2c Fc) only when your study design explicitly requires Fc effector function, e.g. when PD-1+ Treg or PD-1+ exhausted CD8+ T-cell depletion is a desired part of the mechanism, or when you are intentionally comparing Fc-competent versus Fc-silenced checkpoint blockade. If you are uncertain, the Fc-silenced LALAPG format (m2cLA) is the more conservative, “blockade-only” default.
Q: Will PA007162.m2cLA (mIgG2c LALAPG) deplete PD-1+ cells in vivo?
A: No. PD-1-positive cell depletion in vivo by anti-PD-1 antibodies is strictly Fc-dependent: it requires the antibody Fc to engage activating FcγRs (predominantly mFcγRIV on mouse monocytes, macrophages and NK cells, plus FcγRIII on neutrophils) to trigger ADCC and, more importantly, ADCP of PD-1-expressing cells. Because LALAPG mutations abolish detectable binding to all mouse FcγRs and C1q, PA007162.m2cLA acts as a non-depleting, receptor-blocking antibody — it blocks PD-1/PD-L1 and PD-1/PD-L2 signaling but does not kill or phagocytose PD-1+ T cells, B cells or myeloid cells. This is a key difference from the intact-Fc mIgG2c format (PA007162.m2c), which has been reported to deplete PD-1+ cells via FcγR-dependent mechanisms in vivo.
Q: What is the recommended in vivo dosage and administration schedule for PA007162.m2cLA in C57BL/6 tumor models?
A: As a starting dose for checkpoint blockade in C57BL/6 syngeneic models (MC38, B16-F10, LLC, Hepa1-6), we recommend 100–250 µg per mouse per dose, administered by intraperitoneal (i.p.) injection every 2–3 days (typically 200 µg i.p. q3d) for the duration of the study, starting when tumors are established (commonly ~50–100 mm3) or according to your specific protocol. Actual doses should be titrated to your model and readout; some long-term or combination studies use 10 mg/kg every 3–5 days. Always filter the antibody through a 0.2 µm sterile filter immediately before injection and pair dosing with the matching isotype control — In Vivo Grade Mouse IgG2c LALAPG (Fc-silenced) Isotype Control Antibody (catalog PA007141.m2cLA) — at the same dose, route and schedule.
Q: Which isotype control should I pair with PA007162.m2cLA in C57BL/6 studies?
A: Pair PA007162.m2cLA with the In Vivo Grade Mouse IgG2c LALAPG (Fc-silenced) Isotype Control Antibody (catalog PA007141.m2cLA). This control has an irrelevant antigen specificity (e.g. anti-HEL or anti-dansyl/DNP) but an identical mouse IgG2c LALAPG Fc backbone, endotoxin, purity and formulation, so it controls for non-specific Fc effects, protein burden and injection stress in C57BL/6 and other Igh-1b strains. Do not use an intact-Fc mouse IgG2c isotype control or a rat IgG2c isotype control with PA007162.m2cLA, as those have different FcγR engagement profiles and will not control properly for Fc-silenced conditions.
Q: Why is the antibody supplied as a 0.2 µm filtered solution, and do I need to re-filter before in vivo injection?
A: PA007162.m2cLA is supplied as a sterile, endotoxin-low (<1 EU/mg), 0.2 µm-filtered solution in 1× PBS. The 0.2 µm (not 0.2 μM — that is a common unit error) filtration removes particulates, microbial contaminants and trace aggregates that could cause adverse reactions after i.v. or i.p. injection. For most in vivo use the product can be injected directly after gentle mixing and warming to room temperature; however, if the antibody has undergone freeze-thaw, been stored for an extended period at 2–8 °C, or is being administered intravenously, we recommend an additional 0.2 µm sterile syringe filtration immediately before injection to remove any micro-aggregates that may have formed. Avoid repeated freeze-thaw cycles; store aliquots at −20 °C to −70 °C for long-term use.







